Atropine in topical formulations for the management of anterior and posterior segment ocular diseases

INTRODUCTION

Atropine is an old-known drug which is gaining increasing attention due to the myriad of therapeutic effects it may trigger on eye structures. Nevertheless, novel applications may require more adequate topical formulations.

AREAS COVERED

This review aims to gather the existing knowledge about atropine and its clinical applications in the ophthalmological field when administered topically. Atropine ocular pharmacokinetics is paid a special attention, including recent evidences of the capability of the drug to access to the posterior segment. Ocular bioavailability and systemic bioavailability are counterbalanced. Finally, limitations of traditional dosage forms and potential advantages of under investigation delivery systems are analyzed.

EXPERT OPINION

Mydriasis and cyclopegia have been widely exploited for eye examination, management of anterior segment diseases, and more recently as antidotes of chemical weapons. Improved knowledge on drug receptors and related pathways explains atropine repositioning as an outstanding tool to prevent myopia. The ease with which atropine penetrates ocular tissues is a double edged sword, that is, while it ensures therapeutic levels in the posterior segment, the unspecific distribution causes a wide variety of untoward effects. The design of formulations that can selectively deliver atropine to the target tissue for each specific application is an urgent unmet need.

Sustained release of antibiotics from uniform poly (ε-caprolactone) microspheres prepared by a simple fluidic device with a tapered glass capillary

Uniform poly(ε-caprolactone) microspheres containing a variety of water-soluble antibiotics, such as tobramycin, vancomycin, and gentamicin, were prepared by a simple fluidic device with a pristine or tapered glass capillary. Each type of antibiotic was dispersed in an organic solvent by ball-milling prior to microsphere preparation. The poly(ε-caprolactone) organic solution containing the powder of each antibiotic was introduced as the discontinuous phase into the fluidic device, where an aqueous phase containing surfactant served as the continuous phase. The poly(ε-caprolactone) microspheres were obtained after solvent evaporation. A tapered glass capillary was tested to produce poly(ε-caprolactone) microspheres, leading to the size reduction of the microspheres from 47.46 ± 0.72 to 25.49 ± 1.05 µm without destroying size uniformity. This size range should be suitable for parenteral injection into the human body. The release analysis revealed that gentamicin and vancomycin were released from the poly(ε-caprolactone) microspheres up to approximately 2 months in a more sustained manner than tobramycin, which is due to the solubility difference in the antibiotics in water. The antimicrobial activities of each type of antibiotic released from the poly(ε-caprolactone) microspheres were evaluated using Staphylococcus aureus and Escherichia coli.

Human endothelial cell attachment and proliferation on a novel vascular graft prototype

A new vascular prosthesis prototype was assessed for its ability to support an endothelial cell layer in vitro. A coiled tubular structure, constructed from polymer-coated metallic wires, with an internal diameter of 690 microm, was used. Addition of heparin to the surface coating of the coil strongly enhanced the blood compatibility of the device. A series of coils with five different coatings, increasing in hydrophilicity, was studied. Heparin was added to one series, another series did not contain this anticoagulant drug. Upon contact with blood, a vascular prosthesis will instantaneously adsorb plasma proteins on its surface, and these proteins will influence the behavior of cells binding to the device. When coils were treated with human plasma proteins, mimicking the in vivo situation, human microvascular endothelial cells grew well on all coils studied, irrespective of the hydrophilicity of the underlying coating or the addition of heparin. For control coils, only endothelial cell growth on the most hydrophobic surfaces, and a moderate enhancing effect for heparin, were observed. This novel vascular graft prototype seems well suited for the support of an endothelial cell layer, especially when plasma proteins are adsorbed to its surface, and shows promise for in vivo testing.